Biolase, Inc. (BIOL): Debts to Book Capitalization

Brandmark of BIOLASE Inc. (BIOL)

BIOLASE, Inc. (BIOL), a leader in the dental laser segment, is betting on the popularity of painless methodologies, yet is currently forced to divest assets to protect capital from creditors. The debt-to-capitalization ratio on the balance sheet clearly demonstrates the movement of funds, while 0.00 determines the latest valuation metric. Management possesses deep technical expertise but faces conservatism across the broader consumer market.

BIOL - Biolase Inc. Debts to Net Assets over the range 07/04/2022 - 08/04/2024
Original product of BIOLASE Inc.

The scale of production automation at BIOLASE, Inc. (BIOL) is reflected in the dynamics of the current leverage ratio relative to balance sheet capital. This metric determines the share of debt financing relative to the company's equity. The calculation is based on the ratio of total liabilities to the book value of assets minus debt. Investments in robotic optical assembly lines require monitoring of this indicator to assess the debt load. The stability of this value confirms the financial resilience of this high-tech business.

Competitors of BIOLASE, Inc.

BSX: Debts to Book Capitalization|Debts to Book Value edwards.com EW|RMD: Debts to Book Capitalization|PODD - Debt to Book Value|Zimmer Biomet - Debts to Book Capitalization|CooperSurgical (COO) - Debts to Net Assets|ALGN (Align Technology, Inc.) - Debts to Book Capitalization|Debts to Book Capitalization GMED|Debt to Book Capitalization Ratio TransMedics Organ Care System (TMDX)|Debt to Book Capitalization Ratio Alphatec Holdings (ATEC)|Debts to Book Capitalization AORT|ENOV - Debts to Net Assets|Debt to Book Value Integra LifeSciences|ESTA - Debts to Book Capitalization Ratio|Debts to Book Capitalization BBNX|IRADIMED Corp (IRMD) - Debts to Book Value|Debts to Book Capitalization Embecta Inc. (EMBC)|Debt to Book Value Ratio Tandem Corp (TNDM)|AxoGen, Inc. (AXGN) - Debt to Book Value|Debt to Net Assets Ratio SIBN (si-bone.com)|Orthofix - Debt to Book Capitalization Ratio|Debt to Book Value Bioventus Inc BVS|KIDS (OrthoPediatrics Inc.) - Debts to Book Capitalization|TMCI - Debts to Book Value|Debts to Book Capitalization Strata Critical Medical Inc|carlsmed.com (CARL) - Debt to Book Value Ratio|RXST: Debts to Book Capitalization|Debts to Net Assets ClearPoint|Debts to Book Capitalization STXS (Stereotaxis Corp)|Debt to Book Value Neuronetics, Inc (STIM)|Debts to Book Capitalization SGHT (Sight Sciences, Inc.)|Orchestra BioMed Inc. - Debts to Book Capitalization|ANIK - Debt to Book Capitalization Ratio|InspireMD Inc (NSPR) - Debt to Book Capitalization Ratio|Debt to Book Value zhjmedical.com ZJYL|Vivani Medical (VANI) - Debt to Net Assets Ratio|Debts to Book Capitalization XTNT (Xtant Medical Holdings, Inc.)|Debts to Book Value NMTC|MODD: Debt to Book Capitalization Ratio|Debt to Net Assets Myomo Inc. MYO|Debt to Book Value COCH (Envoy Medical, Inc)|Debts to Book Capitalization Vivos Therapeutics Inc VVOS|Debts to Book Capitalization NVNO (enVVeno Medical)|SINT: Debts to Net Assets|Debt to Book Capitalization Ratio Tenon Medical (TNON)|LFWD (ReWalk Robotics) - Debts to Book Capitalization Ratio|Debt to Book Capitalization Ratio AMIX|Debt to Book Value INVO Fertility Corp|Bone Biologics - Debts to Book Capitalization|Debts to Book Value AXNX (axonics.com)|DYNT - Debt to Book Capitalization Ratio|FNA - Debt to Book Value Ratio|Debt to Book Value INVO Bio INVO